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PATIENTOUTCOMES BY CONDITIONING REGIMEN
Median Day 7
TNFR1 Levels (pg/mL)
Mean Day 7 TNFR1
Levels (pg/mL)
Day 100 Grade
2-4 GVHD
Day 100 Grade
3-4 GVHD
Day 100
NRM
2 year
NRM
2 year
OS
Overall (n5 96) 2518 3053 53% 23% 16% 34% 55%
FluBu4 (n5 31) 1735 1897 39% 11% 0% 12% 70%
BCNU/Busulfan (n5 36) 2552 3009 61% 25% 14% 31% 58%
TBI (n5 29) 3907 4226 62% 32% 34% 55% 38%
S158 Oral Presentationsfirst 100 days (p\0.001), and improved 2 year survival rates (70%
p5 0.03).
Our data suggest that etanercept effectively reduces TNFR1 levels
at day 7 post-HCT, which has previously been correlated with trans-
plant outcomes. The median day 7 TNFR1 levels were statistically
different across conditioning regimens, and those with low
TNFR1 levels had improved outcomes (FluBu4. BCNU/Busul-
fan.TBI). The combination of FluBu4 with etanercept as a prom-
ising regimen for high-risk allogeneic HCT warrants further
investigation.10
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We have previously identified a high risk of primary graft failure
(PGF) in patients with DSA in T-cell depleted haploidentical trans-
plantation (HaploSCT); 3/4 patients with DSA developed PGF
compared with 1/20 patients without DSA. All patients with DSA
against anti-HLA-A, -B and -DRB1 developed PGF, while 1 patient
with anti-DP DSA did not. We hypothesized that anti-DP anti-
bodies may have a significant but less deleterious impact on engraft-
ment and evaluated the occurrence of PGF in 487 patients who
received matched unrelated donor transplants (MUDT) at our insti-
tution after 9/2005. Approximately 80% of the transplants were mis-
matched in HLA-DPB1 in the HvG vector. The presence of DSA
was determined by testing the patients’ sera with a panel of fluores-
cent beads coated with single HLA antigen preparations using
a Luminex platform; results were interpreted as fluorescence
intensity (FI) against DSA mismatch as previously defined by us
(see Table Footer). HLA-A,-B,-C,-DRB1,-DRB3/4/5,-DQB1 and
-DPB1 were typed by high resolution methods. Specificity and
intensity of antibodies is described in the Table. Eight patients had
PGF, and 8 had early death. In each category one had DSA. Median
time to ANC500 was 12 days. We found that 5 patients (1%)
presented DSA in their pre-transplant specimens, all females with
a median age of 49 years, and matched with their donors in 10/10 al-
leles. In all patients the DSA were directed against HLA-DP mole-
cules with intermediate to strong intensities. One patient withNumber Anti-DP DSA
DSA
levels
before
1st SCT
Engrafted
(Y/N)
2nd
SCT
(Y/N)
DSA
levels
before
2nd SCT
Engrafted
(Y/N)
1 DPB1*03DBZB 41 N N N/A N/A
2 DPB1*0401 11 to 21 Y N N/A N/A
3 DPB1*0301 31 N Y 0 Y
4 DPA1*0201
and DPB1*0101
31 Y N N/A N/A
5 DPB1*0101 and
DPB1*1101
31 and 11 Y N N/A N/A
DSA-donor-specific anti-HLA antibodies; Y- yes, N-no; N/A- not applica-
ble; 0 - no DSA, FI\500 or negative; weak (500-1500 FI, 11), interme-
diate (1500-3000 FI, 21), strong (3000-7500 FI, 31); very strong
(.7500 FI, 41).DSA (#1) received rituximab/plasma exchange prior to transplant
to decrease DSA levels and died on day 22 without engraftment. Ex-
cluding the patients with early death, we have found a moderate as-
sociation between anti-DP antibodies and PGF (p5 0.0654). When
early death was considered as a negative event associated with DSA,
a significant association was identified between the presence of anti-
DP DSA and graft failure/early death outcome (p5 0.0108, Fisher’s
Exact Test).
Conclusions:These results, combined with our previous findings in
HaploSCT, suggest that anti-DP DSA compared with DSA against
anti-HLA-A, B or DRB1 may have a lower risk for PGF. The differ-
ences may reside in the lower levels of DP molecules expressed on
cell surface. DSA screening is warranted when considering donors
with HLA mismatches as strategies for donor selection and/or anti-
body level reduction may be needed to decrease the risk of PGF in
allogeneic HSCT from partially HLA-matched donors.11
EVALUATION OF PATIENTSWITH MYELODYSPLASTIC SYNDROME (MDS)
UP TO AGE SEVENTY-FIVE, REFERRED FOR ALLOGENEIC HEMATOPOI-
ETIC CELL TRANSPLANT (HCT) INCLUDING DONOR AVAILABILITY AND
HCT OUTCOMES
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Allogeneic HCT remains the only curative treatment strategy for
patients (pts) with MDS. Moffitt Cancer Center (MCC) has imple-
mented a targeted IV busulfan plus fludarabine (tBuFlu) induction
regimen that is myeloablative, with reduced treatment related toxic-
ity, permitting the expansion of empiric age limitations for HCT up
to 75 years (yrs). From January 2004 on, 243 new pts (NP) with a
diagnosis of MDS or CMML were evaluated for HCT. An alloge-
neic donor was identified in 170 pts and 112 received an HCT.
The median age of the 112 transplant pts was 55.6 yrs (24.8 –
73.5). Sixty pts were older than 55 yrs. At the NP visit, IPSS risk
was Low (11), Int-1 (35), Int-2 (42), and High (21) or not evaluable
(3) (NE). Donors included 49 sibling donors (SIB), 48 matched
unrelated donors (MUD) and 15 mismatched unrelated donors
(mMUD). Median follow-up is 19.3 months (0 – 61.4) and the
Kaplan-Meier overall survival (OS) from NP visit is 77% at one
year and 56% at two years. Overall survival is not statistically differ-
ent between SIB, MUD or mMUD HCT (P5 0.39). In 58 pts who
did not receive a HCT, a donor was identified. (Yes donor, No
HCT) Median age was 57 yrs (19 – 69) with 28 pts older than
55yrs. At the NP visit, IPSS was Low (5), Int-1 (19), Int-2 (17),
High (16) and NE (1). Donors included SIB (14), MUD (27),
mMUD (15), and umbilical cord blood (2). Median follow up is
10.3 months (1.7 – 66.3). Seventy-three pts did not obtain a donor
(No Donor, No HCT). Median age was 64.4 yrs (32.6 – 72.1)
with 65 pts older than 55yrs. IPSS at NP visit was Low (8), Int-1
(16), Int-2 (25), High (16) and NE (8). Median follow up of these
pts is 6.7 months (0.9 – 61.3). For the entire cohort (243 pts), pts
with a donor had significantly improved overall survival vs pts with
no donor (P5 0.003); there was no difference in OS between pts
with a donor who did not proceed to HCT and everyone without
a donor (P5 0.27). Twenty-eight of the 73 pts without a donor
did not have donor searches. If these are excluded, in the remaining
215pts OS for pts with an identified donor was improved compared
to OS of those without a donor (P5 0.009) and pts with a donor and
no HCT had similar OS to those without an identified donor
(P5 0.3). These data demonstrate that 70% of patients can acquire
a suitable allogeneic donor and 47% of patients seen as a HCT new
